Latest Hospital-acquired pneumonia Stories
Using acid suppressive medications, such as proton pump inhibitors and histamine2 receptor antagonists, may increase the risk of developing pneumonia.
SAN DIEGO, Dec. 8, 2010 /PRNewswire/ -- CareFusion (NYSE: CFN), a leading, global medical device company, today announced the launch of Verso(TM) 90 adapter, a component that enables uninterrupted access to a ventilated patient's airway without having to disconnect the patient from the ventilator.
SAN DIEGO, March 29 /PRNewswire-FirstCall/ -- CareFusion (NYSE: CFN), a leading, global medical device company, today announced the launch of the AirLife(TM) Diagnostic Catheter, a kit that helps clinicians obtain lower respiratory tract samples to accurately diagnose lung infections. The AirLife Diagnostic Catheter is designed to include everything a single clinician may need to perform the procedure and relies on advanced "mini" bronchial-alveolar lavage (mini-BAL) technology, a diagnostic...
A new study has shown that nearly 50,000 US medical patients die every year of blood poisoning or pneumonia picked up in hospitals.
NEW YORK, Sept. 22 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Nosocomial Infections: Market Impact on Diagnostics and Therapeutics: (MRSA, HAP, C.
A popular stomach-acid reducer used to prevent stress ulcers in critically ill patients needing breathing machine support increases the risk of those patients contracting pneumonia threefold.
Hospitalized patients who are given acid-suppressive medications are 30 percent more likely to develop pneumonia during their hospital stay, a new study found.
Hospitalized patients who receive acid-suppressive medications such as a proton-pump inhibitor have a 30 percent increased odds of developing pneumonia while in the hospital, according to a study in the May 27 issue of JAMA.
Merck's Drug Will Remain Decision Resources Gold Standard Through 2017, According to a New Report from Decision Resources WALTHAM, Mass., March 3 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a broad-spectrum intravenous antibiotic that has activity against Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA), shows higher efficacy than the current benchmark (Wyeth's...
MALVERN, Penn. and WALTHAM, Mass., Sept.